Navigation Links
WellPoint Announces Consumer Innovation Opportunity
Date:1/10/2008

Company looks to further innovation efforts through Consumer Innovation

Event

INDIANAPOLIS, Jan. 10 /PRNewswire-FirstCall/ -- WellPoint, Inc. (NYSE: WLP) is accepting applications for its first Consumer Innovation Event. The event complements WellPoint's ongoing innovation partnership efforts by providing an accelerated process for identifying and piloting innovative programs and services.

"The health benefits industry is moving toward consumer-focused products and processes," said Chad Pomeroy, WellPoint's Vice President of Consumer Innovation. "As the nation's largest health benefits company, we are committed to being the leader in the development of innovative products and services to help members in WellPoint's health plans manage their health while reining in health care costs and reducing the complexity of the health care system."

The Consumer Innovation Event is sponsored by WellPoint's Consumer Innovation Group and will include a wide-ranging, cross-functional team of WellPoint corporate leaders. Attendees will have the opportunity to present ideas and programs that offer tangible benefits to consumers. Ideas and approaches that specifically address the following are sought:

-- Consumer education and engagement

-- Improving the efficiency of health care delivery and administration

-- Payer, provider and consumer relationships

"Through this event, our goal is to identify at least one organization as a potential partner for an in-market pilot program," Pomeroy said, adding, "There are hundreds of small companies implementing innovative, new health care solutions for consumers today. Through a collaborative partnership, we will be able to leverage WellPoint's strengths with these solutions to impact a broader base of consumers more quickly."

Those interested in participating need to complete and submit an application. All applications will be screened and t
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. WellPoint Appoints Brian A. Sassi as President and CEO of the Companys Consumer Business Unit
2. WellPoint Executive Mark Boxer Recognized as One of Computerworlds 2008 Premier 100 IT Leaders
3. WellPoint Announces Appointment of John Langenus as President of Anthem National Accounts
4. WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
5. WellPoint Announces Appointment of John Cannon III as Executive Vice President & General Counsel
6. WellPoint Provides Support and Resources to Most Vulnerable California Residents
7. WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors
8. WellPoint Reports Third Quarter 2007 Results
9. WellPoint NextRx Receives National Leadership Award for Innovative Web Tool
10. Wellpoint NextRx Receives TIPPS Certification from the HR Policy Association
11. WellPoint Announces Realignment of Core Businesses; Names New Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...ug. 29 /PRNewswire-FirstCall/ -- Landauer, Inc. (N...ors declared a regular,quarterly cash dividend of ...008. The dividend will be paid on October 3, 2008,... About Landauer, Landauer is the leading provide... and environmental radiation exposure. For more th...
(Date:8/29/2008)...fic obligation reduced from $250 to $19 million, ...oston Scientific,Corporation (NYSE: BSX ) today a... Texas found two patents of Medtronic, Inc. (NYSE:...ng the prosecution of the patents,before the Unite... previously found that certain Boston Scientific b...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal Center for O...ia to provide protection for cash paying patients ...ic community is benefiting. , .... Milton Owens and the Coastal Center for Obesity ...rovide protection for cash paying patients in the ...
(Date:8/29/2008)... Trusted life science software provider allows...ngage via GSA. , Reston, ...erging software engineering firm dedicated to the...ral Services Administration (GSA) Contract. The GS...h the ability to conveniently engage 5AM Solutions...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2
... Citys smoking rate has shown a decline, thanks to...okers to kick the habit. The statistics in the 200...0%, in comparison to 2002 figures. Over the past y...rom 22.5% to 19.9%) and among Hispanics (from 20.2...
... molecular on switch triggers gene activity that ...abilities to glucose production in the liver was ...earch hospital . The on switch, a protein called...ule that binds to a section of DNA near a gene and...
... in Tamil Nadu, who allegedly tried to get his 15-... to perform a caesarean operation , today said the... him. Dr. Murugan rubbished the media reports that...n Dhileepan Raj, a tenth standard student, operati...
...stoma typically occurs as a solid tumor in the ab...veloping in the network of the body's sympathetic ... rare, but among them, neuroblastoma is a special ...t of all childhood cancers, but 15 percent of chil...
Other Medicine News:Health News:New York Records Decline in Smoking Rate 2Health News:Research Studies on Molecular Switches of Gene 2Health News:The Bottleneck in Neuroblastoma 2
(Date:8/27/2008)...in Parts of Bucks, Delaware, Montgomery,Philadelp...e-USNewswire/ -- After encouraging,results followi...tment of,Environmental Protection will continue it...st the mosquito-borne West Nile virus., Targeted ....m. and,midnight in portions of Bucks, Delaware, M...
(Date:8/27/2008)..., melphalan and prednisone arm demonstrated a, si... complete response -, CAMBRIDGE, Mass., Aug. 27 /...pany today announced the publication of results fr... trial in this week,s edition of the,New England J...nt survival,benefit and a 30 percent complete remi...
(Date:8/27/2008)...7 /-, - Oralair(R) Grasses...acodynamic Study Conducted in an Allergen Challeng... positive results of a new study,conducted in an A...alair(R) Grasses included 86 adult patients expose...nt durations: 1 week, 1 month,2 and 4 months with...
(Date:8/27/2008)...rom BLISS-52 trial, expected by mid-2009 - - Data...fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswire-... HGSI ) today announced it has completed enrollme...wo pivotal Phase 3,randomized clinical trials of L... systemic lupus erythematosus (SLE). Belimumab is ...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Hiemstra Approved to Manufacture Medical Devices in New CER 9345 1Hiemstra Approved to Manufacture Medical Devices in New CER 9345 2TeamStaff Receives Nasdaq Determination Letter 9340 1TeamStaff Receives Nasdaq Determination Letter 9340 2TeamStaff Receives Nasdaq Determination Letter 9340 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 1Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 2Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 4Chromosome Abnormalities Raise Risk for Autism 9333 1Chromosome Abnormalities Raise Risk for Autism 9333 2Chromosome Abnormalities Raise Risk for Autism 9333 3Chromosome Abnormalities Raise Risk for Autism 9333 4
...Family History of ESRD Are at High,Risk , ,WASHIN...f U.S.,adults have a family history of end-stage r...to be at increased risk of developing,kidney disea...l of,the American Society of Nephrology. , "A fami...frican-Americans, who are also at substantially hi...
...ibody significantly reduced the number of,new or e...bmitted,for presentation at upcoming medical meeti...12, 2007,/PRNewswire-FirstCall/ -- Biogen Idec, In...hat the ongoing CHOICE trial, a Phase 2,randomize...zumab,met its primary endpoint in relapsing multi...
Other Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5
...nterior Spinal Implant system. Material that has a...cal bone. The result is an implant that meets the ..., while optimizing the fusion environment through ...omic design with 5 and 10 degrees of lordosis. Min...
...Cage System provides anterior column support for s...ctomies from T1 to L5. The system consists of one ...tacked to a desired height, accommodating various ...lymer material emulates the biomechanical properti...
The primary goals in interbody fusion are to immobilize the affected vertebrae, to restore disc space height and sagittal alignment, and to provide an enviroment for bone fusion between vertebral bod
Flexoscope images are transmitted through sorted fiberglass bundles that record the picture and transmit it to a user's eye. Karl Storz flexoscopes are designed for rough, industrial handling and can
Medicine Products: